| Meridia (sibutramine) / AbbVie |
NCT00261911: A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety. |
|
|
| Completed | 3 | 498 | US | sibutramine | Abbott | Obesity | | 02/02 | | |
NCT00645255: Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects |
|
|
| Terminated | 3 | 466 | US | placebo, sibutramine or placebo, ABT-911, Meridia, sibutramine | Abbott | Obesity, Weight Loss | 01/03 | | | |
HOS, NCT00679653: Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives |
|
|
| Completed | 3 | 171 | Europe | sibutramine, ABT-991, Meridia, Reductil, verapamil/trandolapril, metoprolol/HCT, felodipine/ramipril | Abbott | Obesity, Hypertension | 12/03 | | | |
NCT00677391: Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population |
|
|
| Completed | 3 | 103 | RoW | Sibutramine, ABT-991, Meridia, Reductil, Placebo | Abbott | Obesity | 11/04 | | | |
NCT00165685: A Comparative Study of KES524 in Patients With Obesity Disease |
|
|
| Completed | 3 | | Japan | Sibutramine Hydrochloride Monohydrate | Eisai Limited | Obesity | 03/07 | 03/07 | | |
NCT00402584: A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder |
|
|
| Completed | 3 | 304 | US | sibutramine | Abbott | Binge Eating Disorder, Obesity | | | | |
SCOUT, NCT00234832: A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
|
|
| Completed | 3 | 10777 | US | Sibutramine hydrochloride, ABT-991, sibutramine, Meridia, Reductil, Placebo | Abbott | Obesity | 03/09 | 11/09 | | |
|
NCT00941382: Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients |
|
|
| Unknown status | 3 | 60 | RoW | Sibutramine-Metformin, combination therapy, Sibutramine, Sibutramine monohidrate Hydrochloride, Metformin, Metformin Hydrochloride | Laboratorios Silanes S.A. de C.V. | Obesity | 08/09 | 09/09 | | |
NCT01047657: Effects of Weight Loss in Obese Difficult-to-treat Asthmatics |
|
|
| Completed | 3 | 33 | RoW | Low caloric diet plus orlistat and sibutramine | University of Sao Paulo General Hospital, Fundação de Amparo à Pesquisa do Estado de São Paulo | Asthma, Obesity, Weight Loss | 12/10 | 12/10 | | |
UNLIMITED, NCT05209984: A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight |
|
|
| Withdrawn | 3 | 1855 | RoW | ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg, EF178 15/75mg, ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg, EF178 15/100mg, SIB Group Sibus (Sibutramine) 15mg, Sibutramine 15mg, Placebo Group, Ef178 Placebo | Eurofarma Laboratorios S.A. | Overweight, Obesity | 03/28 | 03/28 | | |
